Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
691 stopped studies mapped to Malignant Head and Neck Neoplasm and descendants · 92% state a reason
Over the 691 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04266730 | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With…(PANDA-VAC) | Phase 1 | suspended | Feb 12, 2020 | UNC Lineberger Comprehensive Cancer Center | Not stated | Other (stated, no rule matched) |
| NCT06974734 | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or… | Phase 1 | terminated | May 16, 2025 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT03953352 | Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck…(GIRAFE) | N/A | withdrawn | May 16, 2019 | Institut Claudius Regaud | Study cancelled | Other (stated, no rule matched) |
| NCT02819752 | PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and…(PEACH) | Phase 1 | terminated | Jun 30, 2016 | Royal Marsden NHS Foundation Trust | funding pulled | Funding |
| NCT06110195 | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Phase 1 | terminated | Oct 31, 2023 | University of Chicago | Drug no longer being developed by manufacturer | Drug supply |
| NCT03386357 | Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma… | Phase 2 | terminated | Dec 29, 2017 | University of Erlangen-Nürnberg Medical School | slow recruitment | Enrollment / accrual |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT02997332 | Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head…(MEDINDUCTION) | Phase 1 | terminated | Dec 20, 2016 | Gustave Roussy, Cancer Campus, Grand Paris | Toxicities due to the treatment, stop of enrollment | Safety / toxicity |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory…(DUTHY) | Phase 2 | terminated | Nov 27, 2018 | Grupo Espanol de Tumores Neuroendocrinos | In compliance with current legislation applicable to Clinical Trials, following the instructions of… | Other (stated, no rule matched) |
| NCT05956795 | Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous… | — | terminated | Jul 21, 2023 | Johns Hopkins University | Expired in IRB | Other (stated, no rule matched) |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT05388136 | Trial Comparing Different Follow-up Strategies(DeintensiF) | N/A | terminated | May 24, 2022 | Insel Gruppe AG, University Hospital Bern | Lack of funding | Funding |
| NCT05192837 | Preoperative Smoking Cessation in Patients Undergoing Surgery(PORTICO) | N/A | terminated | Jan 14, 2022 | Luzerner Kantonsspital | The study is being terminated prematurely due to insufficient participant recruitment. | Enrollment / accrual |
| NCT05296135 | Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer(PREDAPT-HNSCC2) | — | withdrawn | Mar 25, 2022 | Cofactor Genomics, Inc. | No patients were recruited or enrolled in this study. | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT05386550 | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk,… | Phase 3 | terminated | May 23, 2022 | EMD Serono Research & Development Institute, Inc. | The study was terminated by sponsor as the development program was discontinued due to outcome of… | Other (stated, no rule matched) |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | N/A | withdrawn | May 9, 2023 | University of Oklahoma | Study withdrawn due to lack of accrual. | Enrollment / accrual |
| NCT05814666 | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC(PEMDA-HN) | Phase 2 | terminated | Apr 18, 2023 | Flamingo Therapeutics NV | Interim analysis was negative | Efficacy / futility |
| NCT05014698 | IDEntification of New Predisposition Genes in Differentiated THYroid Cancer(IDENTHY-K) | N/A | terminated | Aug 20, 2021 | Nantes University Hospital | end-of-study visit not completed within the protocol timeframe | Other (stated, no rule matched) |
| NCT04862455 | NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic… | Phase 2 | terminated | Apr 28, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05070247 | A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced… | Phase 1 / Phase 2 | terminated | Oct 7, 2021 | Takeda | Clinical Futility of TAK 500 met. No further development with this compound | Efficacy / futility |
| NCT06322576 | 177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma | Phase 2 | terminated | Mar 21, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Sponsor is no longer producing the study drug, so it was not possible to complete the study. | Other (stated, no rule matched) |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally… | Phase 1 / Phase 2 | terminated | Feb 7, 2020 | Ocellaris Pharma, Inc. | Business Decision | Sponsor / business decision |
| NCT05194072 | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors | Phase 1 | terminated | Jan 18, 2022 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04801472 | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients…(OPPIDOM) | N/A | terminated | Mar 17, 2021 | Institut de cancérologie Strasbourg Europe | organisationnal reason | Other (stated, no rule matched) |
| NCT04840472 | Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer | Phase 1 | suspended | Apr 12, 2021 | Stanford University | tentatively suspended until drug manufacturing is available | Drug supply |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or… | N/A | withdrawn | Sep 19, 2024 | Duke University | Changing priorities of portfolio | Sponsor / business decision |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3… | Phase 1 / Phase 2 | withdrawn | Dec 30, 2022 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT04445064 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell…(HN1901) | Phase 2 | terminated | Jun 24, 2020 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | unmet primary endpoint | Other (stated, no rule matched) |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage… | Early Phase 1 | withdrawn | May 6, 2023 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT07268092 | Porcine Extracellular Matrix Nerve Wrap in Neck Dissection for Head and Neck Cancer | N/A | suspended | Dec 5, 2025 | Henry Ford Health System | Dr Tam have collected the first 20 patients for interim analysis per the protocol, and are trying… | Efficacy / futility |
| NCT04741256 | Implementation of a Standardized Tracheostomy Education Discharge Protocol | N/A | withdrawn | Feb 5, 2021 | Case Comprehensive Cancer Center | Other (terminated before study began) | Other (stated, no rule matched) |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04854499 | Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell…(ELEVATE HNSCC) | Phase 2 | terminated | Apr 22, 2021 | Gilead Sciences | Sponsor decision to terminate study | Sponsor / business decision |
| NCT06804850 | Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy… | Phase 2 | withdrawn | Feb 3, 2025 | West China Hospital | The study was withdrawn prior to participant enrollment due to administrative and protocol… | Enrollment / accrual |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT05954676 | Online Peri-operative Education Program for Patients Undergoing Major Head & Neck Surgery | N/A | withdrawn | Jul 20, 2023 | Washington University School of Medicine | Zero accruals | Enrollment / accrual |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06046482 | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for… | Phase 2 | terminated | Sep 21, 2023 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04459715 | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and… | Phase 3 | terminated | Jul 7, 2020 | EMD Serono Research & Development Institute, Inc. | Study has crossed the pre-defined futility boundary at the Interim Analysis. | Efficacy / futility |
| NCT04136912 | 3-D Super Resolution Ultrasound Microvascular Imaging | Phase 2 | terminated | Oct 23, 2019 | UNC Lineberger Comprehensive Cancer Center | Grant ended | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 23, 2026source: clinicaltrials